OTCMKTS:MATN - Mateon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.1150 +0.01 (+9.52 %)
(As of 12/18/2018 04:00 PM ET)
Previous Close$0.1050
Today's Range$0.10 - $0.1150
52-Week Range$0.0520 - $0.3096
Volume30,125 shs
Average Volume49,148 shs
Market Capitalization$5.17 million
P/E Ratio-0.22
Dividend YieldN/A
Beta1.73
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MATN
Previous SymbolNASDAQ:MATN
CUSIPN/A
Phone650-635-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.05
Quick Ratio1.05

Price-To-Earnings

Trailing P/E Ratio-0.22
Forward P/E Ratio-1.44
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.02) per share
Price / Book-5.75

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-13,810,000.00
Net MarginsN/A
Return on Equity-4,138.38%
Return on Assets-397.10%

Miscellaneous

Employees5
Outstanding Shares41,420,000
Market Cap$5.17 million
OptionableNot Optionable

Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (OTCMKTS:MATN) announced its quarterly earnings data on Wednesday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.02). View Mateon Therapeutics' Earnings History.

When is Mateon Therapeutics' next earnings date?

Mateon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 15th 2019. View Earnings Estimates for Mateon Therapeutics.

What price target have analysts set for MATN?

1 Wall Street analysts have issued twelve-month price targets for Mateon Therapeutics' shares. Their predictions range from $1.00 to $1.00. On average, they expect Mateon Therapeutics' share price to reach $1.00 in the next year. This suggests a possible upside of 769.6% from the stock's current price. View Analyst Price Targets for Mateon Therapeutics.

What is the consensus analysts' recommendation for Mateon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mateon Therapeutics.

Has Mateon Therapeutics been receiving favorable news coverage?

Press coverage about MATN stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mateon Therapeutics earned a news impact score of 1.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Who are some of Mateon Therapeutics' key competitors?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:
  • Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 60)
  • Mr. Matthew M. Loar, Chief Financial Officer (Age 55)
  • Ms. Shari Annes, Exec. Officer of Investor Relations
  • Dr. Yuval Binur, Exec. VP of Financial
  • Ms. Pamela Ha, Controller

How do I buy shares of Mateon Therapeutics?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of MATN stock can currently be purchased for approximately $0.1150.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $5.17 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Mateon Therapeutics employs 5 workers across the globe.

What is Mateon Therapeutics' official website?

The official website for Mateon Therapeutics is http://www.mateon.com.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]


MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  284
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel